Bladder cancer treatments are hampered by high recurrence, requiring multiple therapeutic interventions which are highly invasive and cause side effects, underscoring the need for innovative treatments. In the pursuit of advancing bladder cancer treatment, immuno-oncology shows promise. This blog delves into the importance of identifying antigens in the development of targeted cancer therapies.  

Obesity is closely connected to autophagy, a vital cellular process impacting metabolic health. Targets which affect autophagy may therefore be a promising therapeutic approach.

Despite progress, there is no cure for AD, necessitating on-going research into biological targets to develop effective treatments. Using Causaly, MAPK14 was identified as a potential target associated with AD progression which has been studied in mice.    

Atopic eczema, the most common type of eczema, significantly impacts quality of life. Its complexity, influenced by genetic, environmental, and immunological factors, underscores the importance of target discovery for innovative treatments. Identifying novel targets may pave the way for more effective treatments that address the underlying causes of disease.

Neuroinflammation plays a key role in the pathogenesis of Parkinson’s Disease (PD). Understanding biological targets associated with neuroinflammation in this disease may pave the way for effective treatments.

Understanding GOF mutations is crucial for developing targeted therapies which inhibit the activity of aberrant proteins. Here, we explored FLT3 and NOTCH1 as GOF mutations associated with leukemia disease progression.

Poor validation of drug targets has been linked to costly clinical failures and low drug approval rates. Identifying promising therapeutic targets is therefore crucial in the management of complex diseases, such as Respiratory Distress Syndrome (RDS). In this use case, RAGE was identified as a potential target for RDS in adults.

SERCA enzymes have emerged as potential therapeutic targets for Polycystic Kidney Disease (PKD), a prevalent hereditary kidney disease estimated to affect over 12 million people worldwide.

Pulmonary fibrosis is a disease where the lungs develop scarring, causing difficulty in breathing and reduced lung function. Oxidoreductases show promise as targets for pulmonary fibrosis due to their pivotal role in modulating oxidative stress and fibrosis.

miRNA therapeutics face numerous challenges including targeted delivery, specificity, stability, immune response, and toxicity. Overcoming these challenges is paramount for success.

Head and neck cancers account for nearly 4% of all cancers in the US. The most common type is oral cancer, estimated to cause over 170,000 global deaths in 2020 alone. These statistics highlight the urgent need for more research and better treatments.

Gastrointestinal (GI) stromal tumors are a rare form of soft tissue sarcoma of the digestive system, primarily affecting the stomach and small intestine. In the US, approximately 6000 new cases of GI stromal tumors are diagnosed each year. Despite their rarity, these tumors are the most prevalent mesenchymal tumors of the GI tract.

Chronic Obstructive Pulmonary Disease (COPD) is a life-threatening respiratory condition caused by airway obstruction. It ranks among the top global causes of death, with over 200 million cases and 3 million deaths reported in 2019.

Diabetes is a complex metabolic disorder which disrupts the balance of blood sugar in the body, affecting over 400 million people worldwide.¹ According to the World Health Organization (WHO), around 1.5 million deaths each year are directly attributable to diabetes, highlighting the critical need for research into this disease.

Dive into groundbreaking research on Renal Cell Cancer, the most common kidney cancer in adults. Our blog explores innovative strategies for target identification, prioritization, and how these contribute to preventing and tackling this disease.

Two targets were chosen for their novelty – transcription factor CEBPB and transport protein MX2, both reported to be associated to Lupus in 2022.

Toll-like receptor 7 (TLR7) has long been associated with the autoimmune disease, lupus. Genetic polymorphisms that result in higher TLR7 expression are associated with increased risk of developing lupus. Aberrant signaling from the protein, which senses single-stranded RNA viruses, is thought to be a mechanism driving the disease: TLR7 drives B cells to produce ‘auto-antibodies’. […]

Lupus is an autoimmune disease which affects about 1 in 1000 people, which commonly causes joint pain, skin rashes and tiredness.

Being able to stay up to date with scientific data and efficiently extracting insights is critical to drug R&D – but currently it is a manual, time-consuming process

On June 9th – 10th 2022, over 400 pharma leaders came to Berlin to take part in Discovery Europe.